Lannett (LCI) delivered earnings and revenue surprises of 3.85% and 8.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Q3 2020 Lannett Company Inc Earnings Call
It's been a mediocre week for Lannett Company, Inc. (NYSE:LCI) shareholders, with the stock dropping 19% to US$7.58 in...
What happened? Shares of Lannett Company (NYSE: LCI) -- a generic drug manufacturer -- are down by 20.3% as of 12:24 p.m. EDT on Thursday. The company released its fiscal third-quarter earnings report after the market closed on Wednesday, and investors were not impressed with Lannett's financial results.
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Q2 2020 Lannett Company Inc Earnings Call
The Northeast Philadelphia generic drug maker said it is currently the only supplier of the generic combination drug lopinavir/ritonavir to the U.S. market.
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 third quarter on Wednesday, May 6, 2020, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.
Lannett Company, Inc. (NYSE:LCI) shareholders should be happy to see the share price up 27% in the last month. But...
Lannett Company, Inc. (NYSE: LCI) today announced that it is set to meet with the U.S. Food and Drug Administration (FDA) on June 9, 2020 to plan next steps for the clinical advancement of its biosimilar insulin glargine partnered product candidate. Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar.
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 second quarter ended December 31, 2019.
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 second quarter on Wednesday, February 5, 2020, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.
Lannett (LCI) delivered earnings and revenue surprises of 0.00% and 5.82%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020.
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 32nd Annual ROTH Conference on March 16, 2020 at 2:30 p.m. PT at The Ritz Carlton, in Laguna Niguel, California.
Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine capsule product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg capsules. Adderall XR® and its generic versions have an estimated IQVIA market value of approximately $1.3 billion for the 12 months ending January 2020, although actual generic market values are expected to be lower.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Lannett Company, Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Lannett Company, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Good afternoon, everyone, and thank you for joining us today to discuss Lannett Company's Fiscal 2020 Third Quarter Financial Results. On the call today are Tim Crew, Chief Executive Officer; and John Kozlowski, the company's Chief Financial Officer.